The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...

Key Takeaways Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with ...

The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in ...

Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

The FDA has cleared Eli Lilly’s obesity drug Zepbound as the first treatment for obstructive sleep apnea in the U.S.

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The Food and Drug Administration has approved Zepbound, a GLP-1 weight-loss drug from Eli Lilly & Co., for the treatment of moderate to severe sleep apnea certain patients with obesity.

The weight loss drug Zepbound has become the first prescription medication approved to treat obstructive sleep apnea. The Food and Drug Administration on Friday authorized the use of Zepbound ...